These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities. Sanz P; Serratosa JM Expert Rev Mol Med; 2020 Sep; 22():e4. PubMed ID: 32938505 [TBL] [Abstract][Full Text] [Related]
25. The progressive myoclonus epilepsies. Minassian BA Prog Brain Res; 2014; 213():113-22. PubMed ID: 25194486 [TBL] [Abstract][Full Text] [Related]
26. [Progressive myoclonic epilepsy: a retrospective study of newly-diagnosed adult patients from a single center]. Zhang J; Zhou J; Ji C; Wu D; Wang K Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):432-436. PubMed ID: 38565508 [TBL] [Abstract][Full Text] [Related]
29. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion. Chambers JK; Thongtharb A; Shiga T; Azakami D; Saito M; Sato M; Morozumi M; Nakayama H; Uchida K Vet Pathol; 2018 Jul; 55(4):543-551. PubMed ID: 29444631 [TBL] [Abstract][Full Text] [Related]
30. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. Joensuu T; Kuronen M; Alakurtti K; Tegelberg S; Hakala P; Aalto A; Huopaniemi L; Aula N; Michellucci R; Eriksson K; Lehesjoki AE Eur J Hum Genet; 2007 Feb; 15(2):185-93. PubMed ID: 17003839 [TBL] [Abstract][Full Text] [Related]
31. [Efficacy of zonisamide in Lafora's disease case and brief review of its use in progressive myoclonic epilepsy]. Rubio-Nazábal E; Álvarez-Pérez P; Cores-Bartolomé C; Lema-Facal T Rev Neurol; 2022 Sep; 75(6):159-163. PubMed ID: 36098450 [TBL] [Abstract][Full Text] [Related]
32. The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy. Orsini A; Valetto A; Bertini V; Esposito M; Carli N; Minassian BA; Bonuccelli A; Peroni D; Michelucci R; Striano P Seizure; 2019 Oct; 71():247-257. PubMed ID: 31476531 [TBL] [Abstract][Full Text] [Related]
33. Retinal vascular pathology in a mouse model of Lafora progressive myoclonus epilepsy. Patil RP; Kumar N; Kaur A; Munian RK; Bhattacharya B; Ganesh S; Parihar R Neurosci Res; 2024 Jul; 204():58-63. PubMed ID: 38458494 [TBL] [Abstract][Full Text] [Related]
35. Superoxide dismutase and glutathione peroxidase function in progressive myoclonus epilepsies. Ben-Menachem E; Kyllerman M; Marklund S Epilepsy Res; 2000 Jun; 40(1):33-9. PubMed ID: 10771256 [TBL] [Abstract][Full Text] [Related]
36. [From gene to disease; progressive myoclonus epilepsy of Unverricht-Lundborg and mutations in the cystatin B gene]. de Haan GJ; Halley DJ; Deelen WH; Lindhout D Ned Tijdschr Geneeskd; 2002 May; 146(18):846-8. PubMed ID: 12038222 [TBL] [Abstract][Full Text] [Related]
37. Utility of Skin Biopsy in a Case of Progressive Myoclonic Epilepsy: Answer. Frantz T; Fortson E; Strowd LC Am J Dermatopathol; 2018 Sep; 40(9):702. PubMed ID: 30124485 [No Abstract] [Full Text] [Related]
38. Tetraplex formation by the progressive myoclonus epilepsy type-1 repeat: implications for instability in the repeat expansion diseases. Saha T; Usdin K FEBS Lett; 2001 Mar; 491(3):184-7. PubMed ID: 11240124 [TBL] [Abstract][Full Text] [Related]
39. Coexistence of Unverricht-Lundborg disease and congenital deafness: molecular resolution of a complex comorbidity. Kecmanović M; Ristić AJ; Sokić D; Keckarević-Marković M; Vojvodić N; Ercegovac M; Janković S; Keckarević D; Savić-Pavićević D; Romac S Epilepsia; 2009 Jun; 50(6):1612-5. PubMed ID: 19170735 [TBL] [Abstract][Full Text] [Related]